UROGENITAL NEOPLASMS
Clinical trials for UROGENITAL NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new UROGENITAL NEOPLASMS trials appear
Sign up with your email to follow new studies for UROGENITAL NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to boost immune system against hard-to-treat urinary cancers
Disease control OngoingThis early-phase study tests two drugs, bintrafusp alfa and PDS01ADC, alone or with targeted radiation, in 100 adults with metastatic bladder, kidney, or other non-prostate genitourinary cancers. The goal is to see if the combination can help the immune system fight cancer better…
Matched conditions: UROGENITAL NEOPLASMS
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug targets rare cancer mutation in early trial
Disease control OngoingThis early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…
Matched conditions: UROGENITAL NEOPLASMS
Phase: PHASE1 • Sponsor: Atavistik Bio, Inc • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New immunotherapy combo may save bladders in cancer patients
Disease control OngoingThis phase 2 trial tests two immunotherapy drugs, nivolumab and relatlimab, given before surgery for stage II-IIIa bladder cancer. The goal is to see if the combination can eliminate the tumor, allowing patients to keep their bladder instead of having it removed. About 90 partici…
Matched conditions: UROGENITAL NEOPLASMS
Phase: PHASE2 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Could a targeted drug delay prostate cancer progression?
Disease control OngoingThis phase 3 trial tests whether adding the targeted drug abemaciclib to standard hormone therapy (abiraterone plus prednisone) can delay cancer growth in men with high-risk prostate cancer that has spread to bones or organs. Participants receive either abemaciclib or a placebo a…
Matched conditions: UROGENITAL NEOPLASMS
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
NanoDoce made available for urogenital cancer patients outside trials
Disease control NO_LONGER_AVAILABLEThis program offers expanded access to NanoDoce for patients with urogenital cancers who cannot join ongoing clinical trials. The goal is to provide the treatment to those in need. No specific eligibility details are listed.
Matched conditions: UROGENITAL NEOPLASMS
Sponsor: NanOlogy, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC